Quantitative assessment of the contribution of sodium-dependent taurocholate co-transporting polypeptide (NTCP) to the hepatic uptake of rosuvastatin, pitavastatin and fluvastatin

Biopharmaceutics and Drug Disposition

Volumn 34, Issue 8, 2013, Pages 452-461

  Bi, Yi An ^a   Qiu, Xi ^a   Rotter, Charles J ^a   Kimoto, Emi ^a   Piotrowski, Mary ^a   Varma, Manthena V ^a   Ei Kattan, Ayman F ^a   Lai, Yurong ^a,b  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

hepatic transport; hepatocytes; NTCP; statins

Indexed keywords

FLUINDOSTATIN; MIDAZOLAM; NADOLOL; PITAVASTATIN; POLYPEPTIDE; ROSUVASTATIN; SODIUM DEPENDENT TAUROCHOLATE COTRANSPORTING POLYPEPTIDE; TAUROCHOLIC ACID; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG TRANSPORT; DRUG UPTAKE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; TRANSCYTOSIS;

HEPATIC TRANSPORT; HEPATOCYTES; NTCP; STATINS;

ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE; CELLS, CULTURED; FATTY ACIDS, MONOUNSATURATED; FEMALE; FLUOROBENZENES; HEPATOCYTES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; LIVER; MIDDLE AGED; ORGANIC ANION TRANSPORTERS, SODIUM-DEPENDENT; PYRIMIDINES; QUINOLINES; SULFONAMIDES; SYMPORTERS;

EID: 84886594154     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1861     Document Type: Article

References (33)

1. Giacomini KM, Huang SM, Tweedie DJ, et al,. Membrane transporters in drug development. Nat Rev Drug Discov 2010; 9: 215-236. DOI: nrd3028 [pii] 10.1038/nrd3028
2. Simonson SG, Raza A, Martin PD, et al,. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 2004; 76: 167-177. doi: 10.1016/j.clpt.2004. 03.010.
3. Meier PJ, Stieger B,. Bile salt transporters. Annu Rev Physiol 2002; 64: 635-661.
4. Kullak-Ublick GA, Stieger B, Meier PJ,. Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology 2004; 126: 322-342.
5. Visser WE, Wong WS, van Mullem AA, Friesema EC, Geyer J, Visser TJ,. Study of the transport of thyroid hormone by transporters of the SLC10 family. Mol Cell Endocrinol 2010; 315: 138-145. doi: 10.1016/j.mce.2009.08.003.
6. Ho RH, Tirona RG, Leake BF, et al,. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 2006; 130: 1793-1806. doi: 10.1053/j.gastro.2006.02.034.
7. Fujino H, Saito T, Ogawa S, Kojima J,. Transporter-mediated influx and efflux mechanisms of pitavastatin a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol 2005; 57: 1305-1311. doi: 10.1211/jpp.57.10.0009.
8. Greupink R, Dillen L, Monshouwer M, Huisman MT, Russel FG,. Interaction of fluvastatin with the liver-specific Na + -dependent taurocholate cotransporting polypeptide (NTCP). Eur J Pharm Sci 2011; 44: 487-496. doi: 10.1016/j.ejps.2011.09.009.
9. Choi MK, Shin HJ, Choi YL, Deng JW, Shin JG, Song IS,. Differential effect of genetic variants of Na(+)-taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors. Xenobiotica 2011; 41: 24-34. doi: 10.3109/00498254.2010.523736.
10. Ho RH, Leake BF, Roberts RL, Lee W, Kim RB,. Ethnicity-dependent polymorphism in Na + -taurocholate cotransporting polypeptide (SLC10A1) reveals a domain critical for bile acid substrate recognition. J Biol Chem 2004; 279: 7213-7222.
11. Kullak-Ublick G, Glasa J, Boker C, et al,. Chlorambucil-taurocholate is transported by bile acid carriers expressed in human hepatocellular carcinomas. Gastroenterology 1997; 113: 1295-1305.
12. Bi YA, Kazolias D, Duignan DB,. Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport. Drug Metab Dispos 2006; 34: 1658-1665. doi: 10.1124/dmd.105.009118.
13. Li N, Nemirovskiy OV, Zhang Y, et al,. Absolute quantification of multidrug resistance-associated protein 2 (MRP2/ABCC2) using liquid chromatography tandem mass spectrometry. Anal Biochem 2008; 380: 211-222.
14. Balogh LM, Kimoto E, Chupka J, Zhang H, Lai Y,. Membrane protein quantification by peptide-based mass spectrometry approaches: studies on the organic anion-transporting polypeptide family. J Proteom Bioinform 2012; S4: 1-8.
15. Qiu X, Bi Y, Balogh L, Lai Y,. Absolute measurement of species differences in sodium taurocholate co-transporting polypeptide (NTCP/Ntcp) and its modulation in cultured hepatocytes. J Pharm Sci 2013; 102: 3552-63.
16. Bi YA, Kimoto E, Sevidal S, et al,. In vitro evaluation of hepatic transporter-mediated clinical drug-drug interactions: hepatocyte model optimization and retrospective investigation. Drug Metab Dispos 2012; 40: 1085-1092. doi: 10.1124/dmd.111.043489.
17. Kimoto E, Yoshida K, Balogh LM, et al,. Characterization of organic anion transporting polypeptide (OATP) expression and its functional contribution to the uptake of substrates in human hepatocytes. Mol Pharm 2012; 9: 3535-3542. doi: 10.1021/mp300379q.
18. Watanabe T, Kusuhara H, Maeda K, Shitara Y, Sugiyama Y,. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther 2009; 328: 652-662. doi: 10.1124/jpet.108.146647.
19. Watanabe T, Kusuhara H, Maeda K, et al,. Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. Drug Metab Dispos 2010; 38: 215-222. doi: 10.1124/dmd.109.030254.
20. Shitara Y, Horie T, Sugiyama Y,. Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci 2006; 27: 425-446. doi: 10.1016/j.ejps.2005.12.003.
21. Barton HA, Lai Y, Goosen TC, et al,. Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond. Expert Opin Drug Metab Toxicol 2013; 0: 1-14. doi: 10.1517/17425255.2013.759210.
22. Lai Y, Varma M, Feng B, et al,. Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability- considerations for drug development. Expert Opin Drug Metab Toxicol 2012; 8: 723-743. doi: 10.1517/17425255.2012.678048.
23. Stieger B,. The role of the sodium-taurocholate cotransporting polypeptide (NTCP) and of the bile salt export pump (BSEP) in physiology and pathophysiology of bile formation. Handb Exp Pharmacol 2011; 201: 205-259. doi: 10.1007/978-3-642-14541-4-5.
24. Lam JL, Benet LZ,. Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes. Drug Metab Dispos 2004; 32: 1311-1316. doi: 10.1124/dmd.32.11.
25. Li M, Yuan H, Li N, et al,. Identification of interspecies difference in efflux transporters of hepatocytes from dog, rat, monkey and human. Eur J Pharm Sci 2008; 35: 114-126. doi: 10.1016/j.ejps.2008.06.008.
26. Soars MG, Webborn PJ, Riley RJ,. Impact of hepatic uptake transporters on pharmacokinetics and drug-drug interactions: use of assays and models for decision making in the pharmaceutical industry. Mol Pharm 2009; 6: 1662-1677. doi: 10.1021/mp800246x.
27. Yabe Y, Galetin A, Houston JB,. Kinetic characterization of rat hepatic uptake of 16 actively transported drugs. Drug Metab Dispos 2011; 39: 1808-1814.
28. Bow DA, Perry JL, Miller DS, Pritchard JB, Brouwer KL,. Localization of P-gp (Abcb1) and Mrp2 (Abcc2) in freshly isolated rat hepatocytes. Drug Metab Dispos 2008; 36: 198-202. doi: 10.1124/dmd.107.018200.
29. Ghibellini G, Vasist LS, Leslie EM, et al,. In vitro-in vivo correlation of hepatobiliary drug clearance in humans. Clin Pharmacol Ther 2007; 81: 406-413. doi: 10.1038/sj.clpt.6100059.
30. Jones HM, Barton HA, Lai Y, et al,. Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data. Drug Metab Dispos 2012; 40: 1007-1017. doi: 10.1124/dmd.111.042994.
31. Varma MV, Lai Y, Feng B, Litchfield J, Goosen TC, Bergman A,. Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions. Pharm Res 2012; 29: 2860-2873. doi: 10.1007/s11095-012-0792-7.
32. Varma MV, Lai Y, Kimoto E, Goosen TC, El-Kattan AF, Kumar V,. Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide. Pharm Res 2013; 30: 1188-1199. doi: 10.1007/s11095-012-0956-5.
33. Niemi M,. Transporter pharmacogenetics and statin toxicity. Clin Pharmacol Ther 2010; 87: 130-133. doi: 10.1038/clpt.2009.197.